PAK1 and neoplasm: Interestingly, we also found that pharmacological inhibition of PAK1 by IPA-3 significantly suppresses tumor growth and lung metastasis of ESCC cells in vivo and in vivo, suggesting PAK1 is promising therapeutic target for ESCC patients.